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α -GalCer has been shown to be a specific and powerful activator
of murine Vα 14+NKT-cells. α -GalCer and Vα 14+NKT-cells have
been shown to have potent anti-tumour activities against a range of
malignancies, including melanoma, both in vitro and in vivo in
mice (Burdin et al, 1999; Kawano et al, 1998; Kobayashi et al,
1995). α -GalCer also specifically activates and induces prolifera-
tion of human invariant Vα 24+NKT-cells, a subpopulation of NK-
cell receptor (NKR-P1A)-expressing T-cells with an invariant
T-cell receptor (Vα 24Jα Q), which are the human counterpart of
murine Vα 14+NKT-cells (Dellabona et al, 1994). Activation of
invariant Vα 24+NKT-cells by α -GalCer is CD1d dependent and
TCR mediated, but is MHC independent (Couedel et al, 1998;
Kawano et al, 1997; Nieda et al, 1999). The anti-tumour activity
and potential for clinical use of α -GalCer in humans are under
investigation. We are examining whether α -GalCer and human
invariant Vα 24+NKT-cells have anti-tumour activities in humans
and also the mechanisms of any apparent anti-tumour activity of
these cells. On the basis of in vivo observations in murine systems,
we hypothesized that α -GalCer might exhibit anti-tumour activity
against human melanoma and that human Vα 24+NKT-cells acti-
vated by α -GalCer-pulsed Mo-DCs might mediate at least some of
these activities (Cui et al, 1997). 
Human invariant Vα 24+NKT-cells activated by α -GalCer have
been shown to have cytotoxic activity in a number of studies
(Couedel et al, 1998; Kawano et al, 1999). They exhibit TCR-
mediated cytotoxic activity against CD1d-expressing cells. This
might represent a form of autoreactivity or occur through recogni-
tion of an unknown endogenous ligand. In either case, it is unlikely
that broad-spectrum anti-tumour cytolytic activity would be
exerted directly through TCR-mediated recognition of CD1d, as
CD1d is expressed only on a limited number of cell lineages
(Calabi F and Bradbury 1991). The anti-tumour activity of
Vα 24+NKT-cells is thus likely to be exerted through alternative
cytotoxic mechanisms. In support of this, we have previously
shown that invariant Vα 24+NKT-cells exhibit cytolytic anti-
tumour activities against some tumour cell lines that do not
express CD1d through killing mechanisms that are distinct from
both those of NK-cells and T-cells (Nicol et al, 1999). Also, the
presence of NKR-P1A receptors, which may be linked to the
cytolytic activity, argues for an important cytotoxic function of
human invariant Vα 24+NKT-cells other than that exerted through
TCR-mediated recognition of CD1d (Azzoni et al, 1998;
Bezouska et al, 1994). Alternatively, the anti-tumour effects could
be exerted through inhibition of proliferation, either by direct
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and the highly specific effect of inducing proliferation and activation of human Vα 24+NKT-cells. We hypothesized that human Vα 24+NKT-
cells activated by α -GalCer might exhibit anti-tumour activity against human melanoma. To investigate this, Vα 24+NKT-cells were generated
from the peripheral blood of patients with melanoma after stimulation with α -GalCer pulsed monocyte-derived dendritic cells (Mo-DCs).
Vα 24+NKT-cells did not exhibit cytolytic activity against the primary autologous or allogeneic melanoma cell lines tested. However,
proliferation of the melanoma cell lines was markedly suppressed by co-culture with activated Vα 24+NKT-cells (mean ± SD inhibition of
proliferation 63.9 ± 1.3%). Culture supernatants of activated Vα 24+NKT-cell cultures stimulated with α -GalCer pulsed Mo-DCs exhibited
similar antiproliferative activities against melanoma cells, indicating that the majority of the inhibitory effects were due to soluble mediators
rather than direct cell-to-cell interactions. This effect was predominantly due to release of IFN-γ , and to a lesser extent IL-12. Other cytokines,
including IL-4 and IL-10, were released but these cytokines had less antiproliferative effects. These in vitro results show that Vα 24+NKT-cells
stimulated by α -GalCer-pulsed Mo-DCs have anti-tumour activities against human melanoma through antiproliferative effects exerted by
soluble mediators rather than cytolytic effects as observed against some other tumours. Induction of local cytokine release by activated
Vα 24+NKT-cells may contribute to clinical anti-tumour effects of α -GalCer. © 2001 Cancer Research Campaign http://www.bjcancer.com
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inhibitory cytokines. To investigate these possibilities, we exam-
ined the cytolytic and anti-proliferative activities of human
invariant Vα 24+NKT-cells against human primary melanoma cell
lines. 
MATERIALS AND METHODS 
Human invariant Vα 24+NKT-cells 
Invariant Vα 24+NKT-cells were established as follows. Fresh
mononuclear cells from patients with melanoma (I1 and J1) were
incubated for 2 h to separate the adherent and non-adherent cells.
The adherent cells (> 90% monocytes) were then cultured with
400 U/ml rhIL-4 (Schering Plough) and 800 U/ml rhGM-CSF
(Schering Plough) for 5–7 days to produce Mo-DCs. The non-
adherent cells were cultured with irradiated (30 Gy) Mo-DCs,
pulsed with 100 ng/ml α -GalCer (Kirin Corp, Gunma, Japan), and
maintained by re-stimulation every 7–10 d with α -GalCer-pulsed
Mo-DCs. After the second stimulation, invariant Vα 24+NKT cells
were separated by positive (Vα 24TCR) magnetic bead sorting
(miniMACS, Miltenyi Biotec, Gladbach, Germany). After further
expansion induced by repeated stimulation with α -GalCer-pulsed
Mo-DC, Vα 24+CD161+CD4+ cells were obtained by positive cell
selection for CD161 by immunomagnetic separation (miniMACS,
Miltenyi Biotec) and flow cytometry (FACS Vantage, Becton
Dickinson, CA, USA). 
Phenotypic analysis 
The cell surface phenotype of the cells expanded in response to 
α -GalCer was determined by single-and 2-colour flow cytometry.
The following monoclonal antibodies (mAbs) were obtained from
Immunotech: FITC-anti-CD3 (UCHT1), anti-CD3 (X35), FITC-
anti-CD4 (13B8.2), PE-anti-CD8 (B9.11), FITC-anti-Vα 24 (C15),
anti-Vβ 11 (c21)PE-anti-P58.1 (EB6), FITC-anti-p58.2 (GL183),
anti-CD16 (3G8), anti-CD56 (N901), PE-anti-CD94 (HP-3B1).
PE-anti-P70 (NKB1; DX9) and anti-NKR-P1A (DX12) were
obtained from Becton Dickinson. 
Target melanoma cell lines 
Primary melanoma cell lines (MO3, MO8 and MO9) were estab-
lished from metastatic deposits in patients (n = 3) with stage 4
melanoma. Phenotypic analysis using antihuman CD1d mono-
clonal antibodies (CD1d51.1) confirmed that the cell lines were
CD1d negative (data not shown). 
Proliferation assays 
The effect on proliferation of the melanoma cell line (M09) of its
co-culture with Vα 24+NKT-cells,  α -GalCer-pulsed Mo-DCs,
culture supernatants (see later) or cytokines, was assessed using
thymidine uptake assays as follows. Irradiated (30 Gy)
Vα 24+NKT-cells (1 × 104 cells/well) and α -GalCer-pulsed Mo-
DCs (5 × 103 cells/well) were cultured with the primary melanoma
cell line, M09 (5 × 103 or 2.5 × 103 cells) for 96 h. During the final
18 h of incubation, 1uCi[3H] thymidine (3H-TdR) was added to
each well. The incorporation of 3H-TdR was determined by liquid
scintillation counting. The results are expressed as the mean ± SD
counts min for 3 cultures. Melanoma cells (1 × 104) were cultured
with and without 50 ul of the supernatant in a total volume of
200 ul in 96-well flat-bottom plates for 72 h. Thymidine uptake
was assessed as mentioned earlier. 
Analysis of culture supernatants 
To obtain supernatants, Vα 24+NKT cells (2 × 105/ml) cultured
with and without α -GalCer-pulsed Mo-DCs (1 × 105/ml) were
suspended in 1 ml AIM-V medium containing 10% AB serum and
cultured in 24-well plates. Supernatants were collected after 2, 3
and 4 d. The concentrations of IFNγ , IL-4, IL-10 and IL-12 in the
supernatants were measured by enzyme-linked immunosorbent
assay (ELISA) (Immunotech, Marseille, France). The effects of
the supernatants on melanoma cell proliferation were assessed as
described earlier. To examine the role of the individual cytokines
in the supernatants on melanoma cell proliferation, the super-
natants or medium were pre-treated with mAb (10 ug/ml) for 30
min before being added to the 3 melanoma cell lines (1 × 104),
which were then cultured for 96 h. Thymidine uptake was assessed
as mentioned earlier. 
RESULTS 
Phenotype of invariant Vα 24+NKT-cells established
from patients with melanoma 
Cells from patients with melanoma (n = 2, J1 and I1) responding to
α -GalCer-pulsed Mo-DCs (CD1d positive, lineage marker nega-
tive) and selected for expression of Vα 24+ TCR were predomi-
nantly CD3+, CD4+, CD8–, CD161+ (NKR-P1A), Vβ 11+ and
negative for Ig-type NK receptors such as p58.1, p58.2 and p70,
the lectin-type NK receptor CD94 and other markers for NK cells
including CD16 and CD56 (Table 1). This phenotype, observed for
both the cases of metastatic melanoma examined, was the same as
that of cells similarly derived from normal donors (Takahashi et al,
2000). The proliferative response of invariant Vα 24+NKT-cells to
autologous Mo-DCs was enhanced by the addition of α -GalCer
(data not shown). Vα 24+NKT-cells did not exhibit any cytolytic
activity against allogeneic and autologous primary melanoma cell
lines (data not shown). 
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Table 1 Phenotypic analysis of purified Vα 24+ CD4+ NKT-cells derived
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established from patients with melanoma 
Invariant Vα 24+NKT-cells did not exhibit any cytolytic activity
against autologous or 3 allogeneic primary melanoma cell lines, or
against the NK target K562. All assays were undertaken at E/T
ratios of 10:1, 20:1 and 50:1, using a conventional 4 h 51Cr release
assay (data not shown). As a positive control for the 51Cr release
assays, we confirmed that the invariant Vα 24+NKT-cell lines eval-
uated had cytolytic activity against the U937 cell line, previously
shown to be highly sensitive to invariant Vα 24+NKT-cell killing
(data not shown). 
Antiproliferative effects of invariant Vα 24+NKT-cells on
melanoma cells 
Co-culture of invariant Vα 24+NKT-cells (J1) and α -GalCer-
pulsed Mo-DCs with melanoma cells resulted in marked inhibition
of the proliferation of melanoma cells (M09) (Figure 1). We
assessed whether this inhibition required direct cell–cell contact
between invariant Vα 24+NKT-cells and melanoma cells or
resulted from soluble factors released by the invariant
Vα 24+NKT-cells. The effect of the culture supernatants of
invariant Vα 24+NKT-cells on melanoma cell proliferation (MO3,
MO8 and MO9) was assessed. Culture supernatants of invariant
Vα 24+NKT-cells stimulated with α -GalCer-pulsed Mo-DCs
produced approximately 70% inhibition of melanoma cell prolifer-
ation. This was similar to the results of the direct co-culture of acti-
vated Vα 24+NKT-cells with target melanoma cells (Figure 1). In
contrast, supernatants of invariant Vα 24+NKT-cells cultured with
α -GalCer but not Mo-DCs (V2, V3 and V4) and of Mo-DCs
cultured in the presence of α -GalCer but not Vα 24+NKT-cells
(M3) did not inhibit melanoma cell proliferation (Figure 2). These
results confirm that the inhibitory effects were due to soluble
factors released during the interaction between invariant
Vα 24+NKT-cells and α -GalCer-pulsed Mo-DCs. These soluble
factors were not released by α -GalCer-pulsed Mo-DCs alone and
the effects were also not observed with α -GalCer alone. 
Release of inhibitory cytokines 
To determine whether this antiproliferative activity resulted from
the release of cytokines known to have the potential to inhibit
tumour cell proliferation, we first assessed the levels of IFN-γ , IL-
4, IL-10 and IL-12 (Figure 3A–D) in the supernatants of invariant
Vα 24+NKT-cell cultures. Supernatants of Vα 24+NKT-cells co-
cultured with α -GalCer-pulsed Mo-DCs were compared with
those of Vα 24+NKT-cells cultured alone. Higher levels of IFN-γ ,
IL-4 and IL-10 were detected in the supernatants of the
Vα 24+NKT-cells co-cultured with α -GalCer-pulsed Mo-DCs than
in those of Vα 24+NKT-cells cultured alone. IL-12 was detected
Anti-tumour activity of Vα 24+NKT cells against melanoma 743
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Figure 1 Inhibition of the proliferation of a melanoma cell line (M09) by
activated Vα 24+NKT-cells. Melanoma cells cultured alone are shown as
black bars and melanoma cells cultured in the presence of activated
Vα 24+NKT-cells are shown as white bars. Results are shown as the
mean ± SD for 3 cultures
Figure 2 Inhibition of the proliferation of melanoma cells by various supernatants. S2, S3 and S4 are supernatants from Vα 24+NKT-cells cultured with 
α -GalCer-pulsed autologous Mo-DCs for 2, 3 and 4 days, respectively. V2, V3, V4 are supernatants harvested from 2-, 3-, and 4-day cultures of Vα 24+NKT-
cells without α -GalCer-pulsed Mo-DCs. M3 is supernatant harvested after 3 days of α -GalCer-pulsed Mo-DC culture. Inhibition of proliferation is given as a
percentage of the proliferation with no culture supernatant calculated as follows: (cpm proliferation in medium alone – cpm experimental proliferation)/cpm
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BJOC 01-1973 741-746  20/8/01  3:31 pm  Page 743only in the supernatants of Vα 24+NKT-cells cultured with 
α -GalCer-pulsed Mo-DCs but not in those of Vα 24+NKT-cells
cultured with Mo-DCs or those of α -GalCer-pulsed Mo-DCs and
Mo-DCs (Figure 3D). 
Anti-tumour effects of cytokines released in Vα 24+NKT-
cell cultures 
To determine whether the cytokines released by activated
Vα 24+NKT-cells indeed contribute to their antiproliferative
effects, we examined the antiproliferative effects of recombinant
744 A Kikuchi et al
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Figure 3 Cytokine production, assessed by the level of cytokine in culture supernatants, during co-culture of Vα 24+NKT-cells with and without α -GalCer-
pulsed Mo-DCs
Table 2 Effects of recombinant cytokines on melanoma cell growth 
percentage of proliferation
cytokines
IFNY IL-12 IL-4 IL-10
60 U/ml 600 U/ml 150 pg/ml 1500 pg/ml 2 ng/ml 20 ng/ml 10 ng/ml 100 ng/ml
Allogenic M03 55.1 ±   14.0 39.5 ±   3.0 112.9 ±   29.2 63.4 ±      1.6 90.5 ±   20.9 155.4 ±   23.9 85.3 ±   35.3 99.2 ±   7.6
Autologous M08 52.3 ± 11.2 39.7 ±   3.8 82.9 ±   14.4 75.0 ±   6.3 104.7 ±   31.2 113.8 ±   27.5 92.9 ±   0.5 83.7 ±   0.9
Allogenic M09 45.6 ± 11.2 47.6 ±     3.2 90.4 ±   8.8 74.3 ±   14.3 150.3 ±   5.7 126.0 ±   12.4 93.8 ±   27.5 86.8 ±   0.6
1×104 melanoma cells were cultured in the absence or presence of IFN-γ  (60 U/ml, 600 U/ml), IL-10 (10 ng/ml,100 ng/ml) and IL-12 (150 pg/ml, 1500 pg/ml) for 
72h.  [3H] thymidine was added to each well for the final 18 h of incubation.  The percentage proliferation was calculated as follows: cpm experimental 
proliferation/cpm proliferation/cpm proliferation in medium alone × 100.  Results are shown as the mean ±  SD for 3 cultures.
Table 3 Blocking effects of MAbs on culture supernatant inhibition of melanoma cell growth 
Blocking antibody
None α -IFNγ mAB α -IL-12mAb Isotype control Melanoma cells
(IgG2) (IgG1) α -CD3mAB(IgG2) Mouse IgG1
M03 100 0.8 ± 14.6 93.16 ± 7.3 91.4 ± 18.6 120.0 ± 2.2
M08 100 0.8 ± 18.0 103.2 ± 2.3 100.7 ± 4.7 107.9 ± 6.8
M09 100 48.7 ± 2.5 110.7 ± 4.7 105.1 ± 10.7 100.9 ± 7.6
The results are shown as percentage suppression of proliferation. This was calculated as follows: (cpm proliferation in medium
alone – cpm in the presence of the supernatant treated with mAb)/(cpm proliferation in medium alone – cpm in the presence 
of the supernatant)  100. Results are shown as the mean ± SD for 3 cultures.
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that could inhibit the proliferation of all the 3 melanoma 
cell lines tested. IL-12 also exhibited weak antiproliferative
activity against melanoma cells. IL-4 and IL-10 had minimal or no
effect. Inhibition by the combination of cytokines approached that
by the supernatants of activated Vα 24+NKT-cells (data not
shown). The importance of IFN-γ in the antiproliferative effect
exerted by the supernatants of activated Vα 24+NKT-cells 
was assessed by attempting to block the effect with anti-IFN-γ
monoclonal antibodies. This resulted in complete blocking of the
inhibitory effects of the culture supernatants Vα 24+NKT-cells on
proliferation of melanoma cells in 2 cases (M03 and M08) and a
moderate reduction in the third (M09) (Table 3). As the interac-
tions between α -GalCer-pulsed Mo-DCs and Vα 24+NKT-cells
were found to be necessary for their exertion of inhibitory effects
against melanoma cells and for the release of inhibitory cytokines
by the Vα 24+NKT-cells, we cultured α -GalCer-pulsed Mo-DCs
and Vα 24+NKT-cells separately in transwells to determine
whether direct cell-to-cell contact was required for these effects.
Inhibition of melanoma cell (M09) proliferation by Vα 24+NKT-
cells and the release of high levels of IFN-γ and IL-10 were only
detected when the Vα 24+NKT-cells were co-cultured in direct
contact with α -GalCer-pulsed Mo-DCs and not when the cells
were separated by the porous membrane of the transwell (data not
shown). 
DISCUSSION 
The results presented here are the first to show that human
invariant Vα 24+NKT-cells have anti-tumour effects against
human melanoma and that activation by α -GalCer-pulsed-
dendritic cells is essential for this effect. Our results, using primary
melanoma cell lines established from a series of patients with
metastatic melanoma, confirmed the potentially important anti-
tumour effect of α -GalCer-activated invariant Vα 24+NKT-cells.
However, contrary to our expectations, the predominant anti-
tumour effect on melanoma cells was inhibition of proliferation
rather than direct cytotoxic killing. Activation of Vα 24+NKT-cells
involving direct contact between Vα 24+NKT-cells and α -GalCer-
pulsed dendritic cells was found to be essential for the induction of
cytokine release and antiproliferative anti-tumour activities of the
invariant Vα 24+NKT-cells or their culture supernatants. Invariant
Vα 24+NKT-cells are not activated by α -GalCer alone and α -
GalCer alone does not appear to have any direct anti-tumour
effects under the conditions examined. Supernatants of invariant
Vα 24+NKT-cells cultured with α -GalCer but not Mo-DCs, and
of Mo-DCs cultured in the presence of α -GalCer but not
Vα 24+NKT-cells, did not inhibit melanoma cell proliferation. The
requirement of α -GalCer-pulsed dendritic cells for activation of
the inhibitory functions of CD4+ Vα 24+NKT-cells strongly
suggests that the activation of CD4+ Vα 24+NKT-cells occurs via
α -GalCer presented by the CD1d expressed on dendritic cells to
the Vα 24+TCR, as we have previously reported for CD4–CD8-
Vα 24+NKT-cells. A similar pathway of Vα 24+NKT-cell activa-
tion is also presumed to occur in vivo, although the natural ligand
remains to be identified. 
Activated Vα 24+NKT-cells do not require direct contact
with the target cells to exert their antiproliferative effects, which
appear to be mediated through the release of inhibitory cytokines,
in particular IFN-γ . Blocking studies confirmed that, among all
the factors investigated, IFN-γ contributes the most to the 
antiproliferative effects of activated invariant Vα 24+NKT-cells.
IL-12 is also released but appears to contribute less to the less
antiproliferative effects under these conditions than IFN-γ . Our
results were consistent with previous reports that revealed that
IFN-γ is a potent immunomodulator, and exhibits anti-tumour
activity against melanoma both in vitro and in murine models in
vivo (Fujimoto et al, 1996; Gillis and Williams, 1998). There are
many reports that suggest that IL-12 exerts anti-tumour effects
(Cui et al, 1997; Kitamura et al, 1999; Yue et al, 1999), however,
the underlying mechanisms are still not clear. In our study, IL-12
did not strongly inhibit melanoma cell growth. It has also been
reported that IL-10 produced by tumour cells inhibits the synthesis
macrophage-derived angiogenic factors, and hence tumour growth
and metastasis. In the clinical setting, in patients with melanoma
and possibly other malignancies, therapeutic administration of α -
GalCer or α -GalCer-pulsed dendritic cells may induce prolifera-
tion and activation of Vα 24+NKT-cells, resulting in anti-tumour
effects analogous to those observed in vitro. Whether there exist
anti-tumour effects in addition to those exerted by the release of
inhibitory cytokines remains to be confirmed, however activated
Vα 24+NKT-cells may still have a unique role in anti-tumour
immune therapy if they can release cytokines locally in the region
of tumour cells, allowing far greater concentrations of IFN-γ , 
IL-12 or other soluble mediators with anti-tumour activity to accu-
mulate than can be achieved by systemic administration of these
agents. 
In summary, our results indicate that human invariant
Vα 24+NKT-cells have anti-tumour effects against human
melanoma cells in vitro that could translate into a clinical thera-
peutic effect. These anti-tumour effects are antiproliferative, rather
than cytolytic and result from the release of inhibitory factors
during interactions requiring direct contact between the
Vα 24+NKT-cells and α -GalCer-pulsed dendritic cells. Based on
these results we propose that KRN7000 (α -GalCer) may have
potential therapeutic value against human melanoma with their
effects mediated via invariant Vα 24+NKT-cells. 
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